Free Trial
→ $2 Trillion Disappears Because of Fed's Secretive New Move (From Stansberry Research) (Ad)
NASDAQ:SCLX

Scilex 8/13/2024 Earnings Report

Scilex logo
$4.95 +0.28 (+6.00%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 +0.25 (+5.05%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Scilex EPS Results

Actual EPS
-$6.30
Consensus EPS
-$7.00
Beat/Miss
Beat by +$0.70
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$16.37 million
Expected Revenue
$13.17 million
Beat/Miss
Beat by +$3.20 million
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Date
8/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scilex's next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Scilex Earnings Headlines

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
April 22, 2025 | globenewswire.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine
April 17, 2025 | marketwatch.com
Massive dollar overhaul underway in D.C.?
Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in serious jeopardy leaving some to wonder – is this being done by design? A 25-year economist and investor answers here... and details the exact steps you should be taking with your money to prepare.
April 28, 2025 | Stansberry Research (Ad)
Scilex treatment of pericarditis granted FDA orphan designation
April 17, 2025 | markets.businessinsider.com
Scilex confirms FDA awards orphan drug designation for colchicine
April 17, 2025 | markets.businessinsider.com
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
April 16, 2025 | globenewswire.com
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

View Scilex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles